Home > Dermatology > Topical ruxolitinib continues to show promise for vitiligo

Topical ruxolitinib continues to show promise for vitiligo


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
American Academy of Dermatology Annual Meeting
Reuters Health - 29/03/2022 - A cream formulation of the JAK inhibitor ruxolitinib led to significant repigmentation in adolescents and adults with vitiligo over 52 weeks, according to late-breaking phase-3 data reported at the American Academy of Dermatology annual meeting. "These results are extremely encouraging and highlight the clinical potential of ruxolitinib cream for patients with vitiligo," study presenter Dr. David Rosmarin of Tufts Medical Center, in Boston, said in a news release from Incyte, which makes ruxolitinib cream and funded the study. Vitiligo is chronic autoimmune condition affecting roughly 1.9 to 2.8 million people in the United States. Vitiligo is characterized by depigmentation of skin that results from the loss of pigment-producing melanocytes. Over-activation of the JAK signaling pathway is thought to drive inflammation involved in the development and progression of vitiligo. In two phase-3 studies (TRuE-V1 and TRuE-V2) inv...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on